JP2010065046A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010065046A5 JP2010065046A5 JP2009251464A JP2009251464A JP2010065046A5 JP 2010065046 A5 JP2010065046 A5 JP 2010065046A5 JP 2009251464 A JP2009251464 A JP 2009251464A JP 2009251464 A JP2009251464 A JP 2009251464A JP 2010065046 A5 JP2010065046 A5 JP 2010065046A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- peptide
- amino acid
- sequence
- cell epitope
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- 125000000539 amino acid group Chemical group 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 4
- 230000003941 amyloidogenesis Effects 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims 2
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 125000006850 spacer group Chemical group 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37391402P | 2002-04-19 | 2002-04-19 | |
| US60/373,914 | 2002-04-19 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003586180A Division JP4662719B2 (ja) | 2002-04-19 | 2003-04-07 | アルツハイマー病の処置のための免疫学的方法および組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012249078A Division JP2013075898A (ja) | 2002-04-19 | 2012-11-13 | アルツハイマー病の処置のための免疫学的方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010065046A JP2010065046A (ja) | 2010-03-25 |
| JP2010065046A5 true JP2010065046A5 (enExample) | 2010-11-25 |
| JP5345920B2 JP5345920B2 (ja) | 2013-11-20 |
Family
ID=29251102
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003586180A Expired - Fee Related JP4662719B2 (ja) | 2002-04-19 | 2003-04-07 | アルツハイマー病の処置のための免疫学的方法および組成物 |
| JP2009251464A Expired - Fee Related JP5345920B2 (ja) | 2002-04-19 | 2009-10-30 | アルツハイマー病の処置のための免疫学的方法および組成物 |
| JP2012249078A Withdrawn JP2013075898A (ja) | 2002-04-19 | 2012-11-13 | アルツハイマー病の処置のための免疫学的方法および組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003586180A Expired - Fee Related JP4662719B2 (ja) | 2002-04-19 | 2003-04-07 | アルツハイマー病の処置のための免疫学的方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012249078A Withdrawn JP2013075898A (ja) | 2002-04-19 | 2012-11-13 | アルツハイマー病の処置のための免疫学的方法および組成物 |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US20030232758A1 (enExample) |
| EP (2) | EP1497321B1 (enExample) |
| JP (3) | JP4662719B2 (enExample) |
| KR (1) | KR100994748B1 (enExample) |
| CN (1) | CN100360555C (enExample) |
| AT (1) | ATE514707T1 (enExample) |
| AU (1) | AU2003218560B2 (enExample) |
| CA (1) | CA2481952C (enExample) |
| ES (1) | ES2368907T3 (enExample) |
| IL (3) | IL164643A0 (enExample) |
| MX (1) | MXPA04010255A (enExample) |
| NO (2) | NO335192B1 (enExample) |
| NZ (1) | NZ536064A (enExample) |
| PL (1) | PL209696B1 (enExample) |
| SG (1) | SG173214A1 (enExample) |
| WO (1) | WO2003089460A1 (enExample) |
| ZA (1) | ZA200408811B (enExample) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001268005A1 (en) | 2000-07-07 | 2002-01-21 | Lars Lannfelt | Prevention and treatment of alzheimer's disease |
| CA2504349A1 (en) * | 2001-11-02 | 2003-05-15 | Diagenics International Corporation | Monoclonal antibodies specific for beta-amyloid |
| US20050106626A1 (en) * | 2002-10-20 | 2005-05-19 | George Pieczenik | Ligand binding of amyloid peptide protein epitope |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| US8193250B2 (en) * | 2004-10-22 | 2012-06-05 | Mount Sinai School Of Medicine | Compositions and methods for treating alzheimer's disease and related disorders and promoting a healthy nervous system |
| CA2587487A1 (en) * | 2004-11-12 | 2006-05-18 | Pfizer, Inc. | Method of measuring amyloid-beta peptides |
| KR20180058863A (ko) | 2005-11-30 | 2018-06-01 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
| PT1954718E (pt) | 2005-11-30 | 2014-12-16 | Abbvie Inc | Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos |
| CA2632822C (en) | 2005-12-12 | 2018-08-28 | Ruth Greferath | A beta 1-42 specific monoclonal antibodies with therapeutic properties |
| KR20080103560A (ko) | 2006-02-22 | 2008-11-27 | 가부시끼가이샤 하야시바라 세이부쓰 가가꾸 겐꾸조 | 항 아밀로이드-β-펩티드 항체 생산 유도용 펩티드 백신 |
| PL2004688T5 (pl) | 2006-03-23 | 2014-09-30 | Bioarctic Neuroscience Ab | Ulepszone przeciwciała wobec protofibryli oraz ich zastosowania |
| DE112007001030T5 (de) | 2006-04-28 | 2009-02-26 | Kagoshima University | Amyloid-ß-Fibrillogenese-inhibierendes Peptid |
| PL2468770T3 (pl) | 2006-07-14 | 2018-07-31 | Ac Immune S.A. | Humanizowane przeciwciało przeciw amyloidowi beta |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| WO2008143708A2 (en) * | 2006-12-07 | 2008-11-27 | Mayo Foundation For Medical Education And Research | Methods and materials related to anti-amyloid antibodies |
| HRP20140049T1 (hr) | 2007-01-05 | 2014-02-28 | University Of Zürich | Anti beta-amiloid antitijela i njihova upotreba |
| US20100311767A1 (en) | 2007-02-27 | 2010-12-09 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
| CA2679446C (en) | 2007-03-01 | 2016-05-17 | Probiodrug Ag | New use of glutaminyl cyclase inhibitors |
| US9656991B2 (en) | 2007-04-18 | 2017-05-23 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| EP2586795B1 (en) | 2007-10-05 | 2018-05-16 | Genentech, Inc. | Use of anti-amyloid beta antibody in ocular diseases |
| WO2010024927A2 (en) * | 2008-08-28 | 2010-03-04 | The Research Foundation Of State University Of New York | Treatment of amyloidoses using myelin basic protein and fragments thereof |
| CA2745620C (en) * | 2008-11-28 | 2020-02-18 | Hokko Chemical Industry Co., Ltd. | Transformed soybean plant which accumulates vaccine, and use thereof |
| US8912145B2 (en) | 2008-11-28 | 2014-12-16 | Hokko Chemical Industry Co., Ltd. | Vaccine composition for prophylaxis and/or therapy of Alzheimer's disease |
| CN101797493B (zh) * | 2009-02-06 | 2014-05-21 | 上海抗体药物国家工程研究中心有限公司 | 一种在反应釜中制备亲和层析介质的方法 |
| CN101486768B (zh) * | 2009-02-25 | 2012-05-30 | 吉林大学 | 一种用于治疗阿尔茨海默氏病的抗原蛋白及蛋白基因 |
| WO2010124028A2 (en) * | 2009-04-21 | 2010-10-28 | Vasylyev Sergiy V | Light collection and illumination systems employing planar waveguide |
| BR112012008346B1 (pt) | 2009-09-11 | 2021-12-21 | Vivoryon Therapeutics N.V. | Derivados heterocíclicos, seu processo de preparação, e composição farmacêutica |
| WO2011107530A2 (en) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Novel inhibitors |
| DK2545047T3 (da) | 2010-03-10 | 2014-07-28 | Probiodrug Ag | Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5) |
| MX336196B (es) | 2010-04-15 | 2016-01-11 | Abbvie Inc | Proteinas de union a amiloide beta. |
| EP2560953B1 (en) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
| MY164579A (en) | 2010-07-30 | 2018-01-15 | Ac Immune Sa | Safe and functional humanized antibodies |
| EP3533803B1 (en) | 2010-08-14 | 2021-10-27 | AbbVie Inc. | Anti-amyloid-beta antibodies |
| US20120321694A1 (en) * | 2010-10-27 | 2012-12-20 | Daniel Larocque | Compositions and uses |
| WO2012123563A1 (en) | 2011-03-16 | 2012-09-20 | Probiodrug Ag | Benz imidazole derivatives as inhibitors of glutaminyl cyclase |
| DE102011057019A1 (de) * | 2011-12-23 | 2013-06-27 | Forschungszentrum Jülich GmbH | Standard zur Quantifizierung von pathogenen Aggregaten aus körpereigenen Proteinen |
| JP6130401B2 (ja) * | 2012-01-20 | 2017-05-17 | アンナプラガダ，アナンス | 医学画像を客観的に特徴付けるための方法および組成物 |
| US9534048B2 (en) * | 2012-08-24 | 2017-01-03 | University Health Network | Antibodies to TTR and methods of use |
| HRP20181398T1 (hr) * | 2012-09-12 | 2018-10-19 | Neurimmune Holding Ag | Specifična antitijela za amiloid polipeptida humanih otočića (hiapp) i njegova upotreba |
| KR102308915B1 (ko) | 2012-10-15 | 2021-10-06 | 메디뮨 리미티드 | 아밀로이드 베타에 대한 항체 |
| WO2015017280A1 (en) | 2013-07-28 | 2015-02-05 | Qantu Therapeutics, Inc. | Vaccine formulations that induce a th2 immune response |
| WO2015165968A1 (en) * | 2014-04-29 | 2015-11-05 | Affiris Ag | Treatment and prevention of alzheimer's disease (ad) |
| SMT202100263T1 (it) | 2014-07-10 | 2021-07-12 | Eisai R&D Man Co Ltd | Anticorpi leganti protofibrille a-beta migliorati |
| MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
| CN108699134A (zh) * | 2015-12-10 | 2018-10-23 | 国家生物技术研究所公司 | 淀粉样β-蛋白前体抑制剂结构域的变体 |
| KR20200056465A (ko) * | 2016-11-25 | 2020-05-22 | 주식회사 지뉴브 | 신경줄기세포의 분화 촉진 및 보호용 조성물 및 이를 이용하여 신경재생을 유도하는 방법 |
| JP7368856B2 (ja) | 2017-07-25 | 2023-10-25 | トゥルーバインディング，インコーポレイテッド | Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療 |
| EP4233901A3 (en) | 2017-08-22 | 2023-09-06 | Biogen MA Inc. | Pharmaceutical compositions containing anti-beta amyloid antibodies |
| PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
| EP3700556A2 (en) | 2017-10-25 | 2020-09-02 | Janssen Pharmaceuticals, Inc. | Compositions of phosphorylated tau peptides and uses thereof |
| EP3793583A4 (en) * | 2018-05-18 | 2022-03-09 | Université Laval | USE OF A NOD2 AGONIST FOR THE TREATMENT, PROPHYLAXIS AND/OR DELAYING THE ONSET OF MULTIPLE SCLEROSIS AND ALZHEIMER'S DISEASE |
| CN120058944A (zh) | 2019-01-30 | 2025-05-30 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| MY206596A (en) * | 2019-02-08 | 2024-12-25 | Janssen Pharmaceuticals Inc | Method of safe administration of phosphorylated tau peptide vaccine |
| JP7505713B2 (ja) | 2019-02-22 | 2024-06-25 | ロヨラ メリーマウント ユニバーシティ | アミロイドペプチドバリアント |
| CN114173812A (zh) | 2019-04-24 | 2022-03-11 | 杨森制药公司 | Tau疫苗的异源给予 |
| AU2021217290A1 (en) * | 2020-02-05 | 2022-07-21 | Sumitomo Pharma Co., Ltd. | Determination agent and determination method for tauopathy and dementia-related diseases |
| TW202144387A (zh) * | 2020-02-11 | 2021-12-01 | 美商聯合生物醫學公司 | 針對胰島澱粉樣多肽（iapp）的胜肽免疫原及其預防和治療與聚集iapp相關疾病的製劑 |
| US20230181748A1 (en) * | 2020-05-15 | 2023-06-15 | Vib Vzw | Means and methods for the treatment of pathological aggregation |
| JP2023528797A (ja) | 2020-05-26 | 2023-07-06 | トゥルーバインディング，インコーポレイテッド | ガレクチン－３を遮断することにより炎症性疾患を処置する方法 |
| CN115925987A (zh) * | 2022-02-28 | 2023-04-07 | 安域生物科技(杭州)有限公司 | 基于β-淀粉样蛋白修饰的抗原多肽及其应用 |
| CN115786260B (zh) * | 2022-12-26 | 2024-08-20 | 海南大学 | Aβ42-hIAPP共寡聚化物诱导的AD脑类器官病理模型方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235877A (en) | 1979-06-27 | 1980-11-25 | Merck & Co., Inc. | Liposome particle containing viral or bacterial antigenic subunit |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4666829A (en) * | 1985-05-15 | 1987-05-19 | University Of California | Polypeptide marker for Alzheimer's disease and its use for diagnosis |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| NZ253137A (en) | 1992-06-25 | 1996-08-27 | Smithkline Beecham Biolog | Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a. |
| US5766846A (en) * | 1992-07-10 | 1998-06-16 | Athena Neurosciences | Methods of screening for compounds which inhibit soluble β-amyloid peptide production |
| US5840294A (en) | 1993-03-29 | 1998-11-24 | Queen's University At Kingston | Method for treating amyloidosis |
| US5759551A (en) | 1993-04-27 | 1998-06-02 | United Biomedical, Inc. | Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines |
| CA2161445C (en) * | 1993-04-27 | 2009-06-30 | Anna Efim Ladd | Immunogenic lhrh peptide constructs and synthetic universal immune stimulators for vaccines |
| US5744144A (en) | 1993-07-30 | 1998-04-28 | University Of Pittsburgh University Patent Committee Policy And Procedures | Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| AU6728396A (en) | 1995-08-17 | 1997-03-12 | Ontario Cancer Institute, The | Protein fibril assembly assay |
| US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| US6750324B1 (en) * | 1997-12-02 | 2004-06-15 | Neuralab Limited | Humanized and chimeric N-terminal amyloid beta-antibodies |
| PT1292187E (pt) | 2000-06-20 | 2006-07-31 | Univ Toronto | Modelo animal transgenico de disturbios neurodegenerativos |
| US6310810B1 (en) | 2000-07-14 | 2001-10-30 | Raj Kumar Jain | High-speed sense amplifier |
| US6906169B2 (en) * | 2001-05-25 | 2005-06-14 | United Biomedical, Inc. | Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide |
-
2003
- 2003-04-07 MX MXPA04010255A patent/MXPA04010255A/es unknown
- 2003-04-07 PL PL373450A patent/PL209696B1/pl unknown
- 2003-04-07 AT AT03711746T patent/ATE514707T1/de not_active IP Right Cessation
- 2003-04-07 JP JP2003586180A patent/JP4662719B2/ja not_active Expired - Fee Related
- 2003-04-07 SG SG2006073324A patent/SG173214A1/en unknown
- 2003-04-07 ES ES03711746T patent/ES2368907T3/es not_active Expired - Lifetime
- 2003-04-07 IL IL16464303A patent/IL164643A0/xx unknown
- 2003-04-07 EP EP03711746A patent/EP1497321B1/en not_active Expired - Lifetime
- 2003-04-07 KR KR1020047016794A patent/KR100994748B1/ko not_active Expired - Fee Related
- 2003-04-07 EP EP10182139.5A patent/EP2330113B1/en not_active Expired - Lifetime
- 2003-04-07 NZ NZ536064A patent/NZ536064A/en not_active IP Right Cessation
- 2003-04-07 WO PCT/CA2003/000502 patent/WO2003089460A1/en not_active Ceased
- 2003-04-07 CN CNB038088584A patent/CN100360555C/zh not_active Expired - Fee Related
- 2003-04-07 AU AU2003218560A patent/AU2003218560B2/en not_active Ceased
- 2003-04-07 CA CA2481952A patent/CA2481952C/en not_active Expired - Fee Related
- 2003-04-10 US US10/411,544 patent/US20030232758A1/en not_active Abandoned
-
2004
- 2004-10-17 IL IL164643A patent/IL164643A/en not_active IP Right Cessation
- 2004-11-01 ZA ZA2004/08811A patent/ZA200408811B/en unknown
- 2004-11-18 NO NO20045021A patent/NO335192B1/no not_active IP Right Cessation
-
2005
- 2005-07-13 US US11/180,225 patent/US20090041771A1/en not_active Abandoned
-
2009
- 2009-01-15 IL IL196532A patent/IL196532A/en not_active IP Right Cessation
- 2009-10-30 JP JP2009251464A patent/JP5345920B2/ja not_active Expired - Fee Related
-
2012
- 2012-03-29 US US13/434,205 patent/US20120315321A1/en not_active Abandoned
- 2012-11-13 JP JP2012249078A patent/JP2013075898A/ja not_active Withdrawn
-
2013
- 2013-11-07 NO NO20131483A patent/NO20131483L/no not_active Application Discontinuation
-
2014
- 2014-04-07 US US14/246,830 patent/US20140212481A1/en not_active Abandoned
-
2016
- 2016-06-17 US US15/186,049 patent/US20160297876A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010065046A5 (enExample) | ||
| JP2006505502A5 (enExample) | ||
| JP2010534684A5 (enExample) | ||
| JP2012126742A5 (enExample) | ||
| JP2010535026A5 (enExample) | ||
| JP2009268467A5 (enExample) | ||
| JP2006149395A5 (enExample) | ||
| JP2013539454A5 (enExample) | ||
| NZ593833A (en) | Extended recombinant polypeptides and compositions comprising same | |
| JP2010533478A5 (enExample) | ||
| JP2011515449A5 (enExample) | ||
| JP2009225798A5 (enExample) | ||
| JP2009511579A5 (enExample) | ||
| JP2013048638A5 (enExample) | ||
| JP2008525033A5 (enExample) | ||
| JP2008531734A5 (enExample) | ||
| JP2007513634A5 (enExample) | ||
| EA200870237A1 (ru) | Последовательности пептидов и композиции | |
| JP2011521902A5 (enExample) | ||
| JP2012115277A5 (enExample) | ||
| JP2010265269A5 (enExample) | ||
| JP2010088434A5 (enExample) | ||
| JP2009527503A5 (enExample) | ||
| JP2015505309A5 (enExample) | ||
| JP2009505964A5 (enExample) |